Acquired haemophilia in a patient with neoplastic disease
Journal Title: OncoReview - Year 2012, Vol 2, Issue 4
Abstract
Acquired haemophilia A (AH) is a rare autoimmune disorder caused by inhibitory antibodies against coagulation factor VIII and characterized by spontaneous hemorrhage in patients with no previous personal or family history of bleeding. Morbidity and mortality are high, primarily because of bleeding and adverse effects of immune therapy. In about 12% of cases AH is secondary to malignancy,with two-thirds of associated malignancy being solid tumors. Authors present a case of a 67-year-old patient with AH who experienced several bleeding episodes, which were treated with factorVIII “by-passing agents” including activated prothrombin complex concentrates (aPCC, FEIBA) and recombinant activated factor VIIa (rVIIa, NovoSeven). The patient was resistant to many inhibitor eradication procedures. In the 8th year of follow-up severe gastrointestinal bleeding episodes occurred, diagnosed as due to small intestine tumor with hepatic metastases. The two surgical procedures have been performed, but the patient died in the postoperative period due to cardiac arrest. The postmortem histopathological examination of the small intestine tumor revealed non-Hogdkin lymphoma. The purpose of this report is to increase awareness of the possibility of AH as the reason of bleeding in patients with malignancy as well as to stress, that all invasive procedures in AH areburdened with a high risk of complications which include fatal bleedings despite adequate administration of factor VIII by-passing agents.
Authors and Affiliations
Krystyna Zawilska, Witold Kruger, Mariola Bober, Sławomir Jurek
Keywords
Related Articles
- EP ID EP53186
- DOI -
- Views 206
- Downloads 0
Octreotide LAR in neuroendocrine tumors - a summary of the experience
Neuroendocrine tumors are a rare and heterogeneous group of neoplasms. Most of the patient is diagnosed with locally advanced or metastatic disease and curative surgery is rarely an option. Somatostatin analogues have b...
Cardioncology in Russia: Start-Off and Prospects
The progress in improving the survival of cancer patients in Russia, as well as throughout the world, means that in the next years it is going to be an increase in the number of disabled people who has achieved remission...
The cardiac safety during treatment with sunitinib and sorafenib, multikinase angiogenesis inhibitors
Cardiotoxicity of multikinase angiogenesis inhibitors, sunitinib and sorafenib, is most often myocardial systolic dysfunction or arterial and venous thromboembolic events. Essential risk factor seems to be iatrogenic art...
Adriamycin cardiomyopathy with congestive heart failure, cardiogenic shock and emergency heart transplant: 30-year follow up
Doxorubicin chemotherapeutic agent is widely utilized for many types of cancers since the late 1960s. Cardiomyopathy is a well-known side effect of doxorubicin often limiting its use. In many cases doxorubicin cardiomyop...
Acute coronary syndrome in patients with concomitant neoplastic disease and chemotherapy. Is clinical distinctness possible?
We present 2 cases of acute coronary syndrome in patients with concomitant neoplastic disease during chemotherapy. In both patients, we found unusual angiographic image which showed that despite the presence of very larg...